Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoma | 25 | 2024 | 1802 | 3.120 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 4 | 2024 | 78 | 1.970 |
Why?
|
Gastrointestinal Stromal Tumors | 9 | 2021 | 616 | 1.750 |
Why?
|
Liposarcoma | 9 | 2024 | 288 | 1.670 |
Why?
|
Soft Tissue Neoplasms | 13 | 2024 | 1162 | 1.660 |
Why?
|
Antibiotics, Antineoplastic | 5 | 2024 | 678 | 1.240 |
Why?
|
Sirolimus | 4 | 2024 | 1539 | 1.220 |
Why?
|
Leiomyosarcoma | 5 | 2024 | 426 | 0.900 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 5 | 2019 | 361 | 0.870 |
Why?
|
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2024 | 115 | 0.830 |
Why?
|
Antineoplastic Agents | 19 | 2024 | 13650 | 0.760 |
Why?
|
Protein Kinase Inhibitors | 8 | 2024 | 5693 | 0.670 |
Why?
|
Quinolines | 4 | 2024 | 770 | 0.630 |
Why?
|
Albumins | 1 | 2021 | 577 | 0.630 |
Why?
|
Gastrointestinal Neoplasms | 4 | 2019 | 957 | 0.600 |
Why?
|
Extremities | 2 | 2024 | 870 | 0.580 |
Why?
|
Isoindoles | 1 | 2016 | 36 | 0.530 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2016 | 422 | 0.520 |
Why?
|
Inservice Training | 1 | 2018 | 374 | 0.510 |
Why?
|
Karyopherins | 1 | 2016 | 134 | 0.490 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2013 | 1621 | 0.490 |
Why?
|
Phenylurea Compounds | 3 | 2019 | 531 | 0.480 |
Why?
|
Cytarabine | 1 | 2017 | 695 | 0.480 |
Why?
|
Pyrroles | 7 | 2024 | 1122 | 0.480 |
Why?
|
Aminopyridines | 5 | 2024 | 578 | 0.470 |
Why?
|
Hydrazines | 1 | 2016 | 223 | 0.460 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 12 | 2024 | 11872 | 0.460 |
Why?
|
Cyclin-Dependent Kinase 4 | 2 | 2015 | 562 | 0.440 |
Why?
|
Triazoles | 2 | 2016 | 903 | 0.430 |
Why?
|
Benzoquinones | 1 | 2013 | 198 | 0.420 |
Why?
|
Electron Transport Complex II | 1 | 2012 | 53 | 0.410 |
Why?
|
Benzamides | 4 | 2016 | 1376 | 0.400 |
Why?
|
Pyrrolidinones | 1 | 2012 | 116 | 0.390 |
Why?
|
Lactams, Macrocyclic | 1 | 2013 | 319 | 0.380 |
Why?
|
Granuloma, Plasma Cell | 1 | 2012 | 80 | 0.380 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 857 | 0.380 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2016 | 3608 | 0.370 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2014 | 352 | 0.370 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2012 | 563 | 0.360 |
Why?
|
Doxorubicin | 4 | 2024 | 2229 | 0.360 |
Why?
|
Chondrosarcoma | 1 | 2013 | 305 | 0.350 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2024 | 9410 | 0.350 |
Why?
|
Carbolines | 2 | 2024 | 288 | 0.340 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2012 | 257 | 0.340 |
Why?
|
Molecular Targeted Therapy | 3 | 2018 | 2824 | 0.340 |
Why?
|
Hedgehog Proteins | 1 | 2014 | 771 | 0.340 |
Why?
|
Nanoparticles | 1 | 2021 | 1966 | 0.340 |
Why?
|
Genes, myc | 4 | 2000 | 391 | 0.330 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2019 | 2843 | 0.330 |
Why?
|
Benzimidazoles | 1 | 2014 | 862 | 0.320 |
Why?
|
Bone Neoplasms | 3 | 2022 | 2563 | 0.310 |
Why?
|
Indoles | 6 | 2017 | 1836 | 0.310 |
Why?
|
Sarcoma, Clear Cell | 3 | 2015 | 72 | 0.290 |
Why?
|
Tumor Suppressor Protein p53 | 7 | 2019 | 2952 | 0.290 |
Why?
|
Oncogene Proteins, Fusion | 3 | 2018 | 1608 | 0.290 |
Why?
|
Imidazoles | 1 | 2013 | 1169 | 0.280 |
Why?
|
Middle Aged | 49 | 2024 | 223233 | 0.280 |
Why?
|
Neoplasms | 9 | 2024 | 22350 | 0.270 |
Why?
|
Spiro Compounds | 2 | 2017 | 69 | 0.270 |
Why?
|
Maximum Tolerated Dose | 6 | 2024 | 896 | 0.250 |
Why?
|
Transplantation, Heterologous | 1 | 2014 | 2391 | 0.250 |
Why?
|
Neoplasm Metastasis | 7 | 2024 | 4892 | 0.250 |
Why?
|
Proto-Oncogene Proteins c-myc | 5 | 1996 | 998 | 0.250 |
Why?
|
Adult | 48 | 2024 | 223317 | 0.240 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2019 | 10748 | 0.240 |
Why?
|
Mice, Nude | 4 | 2016 | 3618 | 0.240 |
Why?
|
Aged | 40 | 2024 | 171319 | 0.230 |
Why?
|
Health Personnel | 1 | 2018 | 3387 | 0.230 |
Why?
|
TOR Serine-Threonine Kinases | 5 | 2016 | 2061 | 0.230 |
Why?
|
Genomics | 2 | 2022 | 5924 | 0.230 |
Why?
|
Male | 50 | 2024 | 364203 | 0.230 |
Why?
|
Electronic Health Records | 2 | 2018 | 4881 | 0.220 |
Why?
|
Humans | 77 | 2024 | 767040 | 0.220 |
Why?
|
Sarcoma, Alveolar Soft Part | 2 | 2015 | 44 | 0.220 |
Why?
|
Female | 52 | 2024 | 396660 | 0.220 |
Why?
|
Giant Cell Tumors | 2 | 2015 | 89 | 0.220 |
Why?
|
Administration, Oral | 5 | 2014 | 4026 | 0.210 |
Why?
|
Connective Tissue | 2 | 2022 | 425 | 0.210 |
Why?
|
Cell Cycle | 6 | 2014 | 2927 | 0.210 |
Why?
|
Ketones | 1 | 2024 | 183 | 0.210 |
Why?
|
Furans | 1 | 2024 | 199 | 0.210 |
Why?
|
Fibrosarcoma | 1 | 2024 | 313 | 0.200 |
Why?
|
Receptor, Macrophage Colony-Stimulating Factor | 3 | 2024 | 94 | 0.200 |
Why?
|
Deoxycytidine | 4 | 2019 | 886 | 0.200 |
Why?
|
Hemangiosarcoma | 1 | 2024 | 214 | 0.190 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2019 | 5332 | 0.190 |
Why?
|
Treatment Outcome | 23 | 2024 | 65295 | 0.190 |
Why?
|
Apoptosis | 9 | 2016 | 9513 | 0.190 |
Why?
|
Piperazines | 6 | 2015 | 2548 | 0.180 |
Why?
|
Immunohistochemistry | 6 | 2014 | 11063 | 0.170 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2010 | 2887 | 0.160 |
Why?
|
Piperidones | 1 | 2019 | 37 | 0.160 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2019 | 2428 | 0.160 |
Why?
|
Pathology, Clinical | 1 | 2023 | 374 | 0.160 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2022 | 335 | 0.160 |
Why?
|
Neoplasm Staging | 6 | 2024 | 11217 | 0.150 |
Why?
|
Disease-Free Survival | 7 | 2024 | 6844 | 0.150 |
Why?
|
Neoplasm Proteins | 1 | 2010 | 3599 | 0.150 |
Why?
|
Acetates | 1 | 2019 | 314 | 0.150 |
Why?
|
Tunica Intima | 1 | 2019 | 455 | 0.140 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 18063 | 0.140 |
Why?
|
Cell Line, Tumor | 6 | 2018 | 17097 | 0.140 |
Why?
|
Sarcoma, Synovial | 1 | 2018 | 156 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-kit | 3 | 2016 | 723 | 0.130 |
Why?
|
Endometrial Stromal Tumors | 1 | 2017 | 46 | 0.130 |
Why?
|
Uterine Neoplasms | 2 | 2017 | 1424 | 0.130 |
Why?
|
Pyrimidines | 5 | 2019 | 3044 | 0.130 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2019 | 249 | 0.130 |
Why?
|
Osteosarcoma | 1 | 2022 | 910 | 0.130 |
Why?
|
14-3-3 Proteins | 1 | 2017 | 221 | 0.130 |
Why?
|
Heart Neoplasms | 1 | 2019 | 374 | 0.130 |
Why?
|
DNA Mismatch Repair | 1 | 2019 | 431 | 0.130 |
Why?
|
Neoadjuvant Therapy | 3 | 2024 | 2902 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2023 | 1061 | 0.120 |
Why?
|
Consensus | 2 | 2022 | 3207 | 0.120 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2019 | 645 | 0.120 |
Why?
|
Transcription Factors | 4 | 2010 | 12158 | 0.120 |
Why?
|
Efficiency | 1 | 2018 | 479 | 0.120 |
Why?
|
Dermatofibrosarcoma | 1 | 2015 | 49 | 0.120 |
Why?
|
Lung Neoplasms | 2 | 2018 | 13491 | 0.120 |
Why?
|
Phosphorylation | 3 | 2015 | 8310 | 0.120 |
Why?
|
Reactive Oxygen Species | 1 | 2022 | 2144 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2013 | 2457 | 0.110 |
Why?
|
Benzofurans | 1 | 2014 | 139 | 0.110 |
Why?
|
Retinoblastoma Protein | 2 | 2015 | 670 | 0.110 |
Why?
|
Self Efficacy | 1 | 2018 | 643 | 0.110 |
Why?
|
Ornithine Decarboxylase | 1 | 1993 | 63 | 0.110 |
Why?
|
Injections, Intravenous | 1 | 2016 | 1377 | 0.110 |
Why?
|
Cyclins | 2 | 2001 | 605 | 0.110 |
Why?
|
Paraganglioma, Extra-Adrenal | 1 | 2013 | 47 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2014 | 287 | 0.110 |
Why?
|
Aged, 80 and over | 12 | 2024 | 59548 | 0.110 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2016 | 719 | 0.110 |
Why?
|
Blotting, Western | 3 | 2016 | 5022 | 0.110 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 2014 | 205 | 0.110 |
Why?
|
Biopsy | 3 | 2023 | 6777 | 0.110 |
Why?
|
Gene Fusion | 2 | 2015 | 356 | 0.110 |
Why?
|
Mouth Diseases | 1 | 2015 | 239 | 0.110 |
Why?
|
Succinate Dehydrogenase | 1 | 2013 | 148 | 0.100 |
Why?
|
Lymphatic Metastasis | 2 | 2018 | 2900 | 0.100 |
Why?
|
Biological Products | 1 | 2022 | 948 | 0.100 |
Why?
|
Salvage Therapy | 1 | 2019 | 1271 | 0.100 |
Why?
|
Prospective Studies | 6 | 2022 | 54886 | 0.100 |
Why?
|
Young Adult | 17 | 2024 | 59980 | 0.100 |
Why?
|
Inhibitory Concentration 50 | 1 | 2013 | 464 | 0.100 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 661 | 0.100 |
Why?
|
Phthalazines | 1 | 2014 | 397 | 0.100 |
Why?
|
Hydroxamic Acids | 1 | 2014 | 483 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2018 | 3552 | 0.100 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2015 | 705 | 0.100 |
Why?
|
Retrospective Studies | 12 | 2024 | 81659 | 0.100 |
Why?
|
Synovitis, Pigmented Villonodular | 1 | 2011 | 32 | 0.100 |
Why?
|
Tissue Array Analysis | 1 | 2013 | 545 | 0.090 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 892 | 0.090 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 904 | 0.090 |
Why?
|
Anilides | 2 | 2024 | 413 | 0.090 |
Why?
|
Mutation | 9 | 2022 | 30211 | 0.090 |
Why?
|
Cell Differentiation | 6 | 2016 | 11657 | 0.090 |
Why?
|
Feedback, Physiological | 1 | 2013 | 481 | 0.090 |
Why?
|
Oncogene Proteins | 1 | 2014 | 715 | 0.090 |
Why?
|
Neoplasm Transplantation | 1 | 2014 | 2012 | 0.090 |
Why?
|
Enzyme Activation | 2 | 2013 | 3587 | 0.090 |
Why?
|
Survival Rate | 3 | 2021 | 12823 | 0.080 |
Why?
|
Gene Dosage | 1 | 2014 | 1211 | 0.080 |
Why?
|
GTP Phosphohydrolases | 1 | 2013 | 525 | 0.080 |
Why?
|
Trans-Activators | 2 | 2014 | 2856 | 0.080 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2014 | 777 | 0.080 |
Why?
|
Program Evaluation | 1 | 2018 | 2505 | 0.080 |
Why?
|
Aromatase Inhibitors | 1 | 2013 | 519 | 0.080 |
Why?
|
Drug Administration Schedule | 5 | 2017 | 4855 | 0.080 |
Why?
|
PPAR gamma | 1 | 2012 | 484 | 0.080 |
Why?
|
Thiazolidinediones | 1 | 2012 | 460 | 0.080 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 1993 | 1168 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 4572 | 0.080 |
Why?
|
Receptors, Progesterone | 1 | 2013 | 1159 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 4 | 2001 | 4522 | 0.080 |
Why?
|
Receptors, Estrogen | 2 | 2013 | 2252 | 0.080 |
Why?
|
Receptor, IGF Type 1 | 1 | 2010 | 384 | 0.080 |
Why?
|
Hepatocyte Growth Factor | 1 | 2010 | 268 | 0.080 |
Why?
|
Nitriles | 1 | 2013 | 980 | 0.080 |
Why?
|
Animals | 15 | 2016 | 168965 | 0.080 |
Why?
|
Antibodies, Monoclonal | 3 | 2017 | 9245 | 0.080 |
Why?
|
Prognosis | 5 | 2021 | 29963 | 0.080 |
Why?
|
Gene Expression | 4 | 2014 | 7587 | 0.070 |
Why?
|
Pyridines | 3 | 2019 | 2890 | 0.070 |
Why?
|
Endometrial Neoplasms | 1 | 2017 | 1381 | 0.070 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2013 | 2883 | 0.070 |
Why?
|
Cancer Vaccines | 1 | 2015 | 1041 | 0.070 |
Why?
|
Cell Survival | 2 | 2016 | 5750 | 0.070 |
Why?
|
Medical Oncology | 1 | 2018 | 2341 | 0.070 |
Why?
|
Chromatin | 1 | 2018 | 2980 | 0.070 |
Why?
|
Gene Expression Profiling | 2 | 2019 | 9532 | 0.060 |
Why?
|
MAP Kinase Signaling System | 1 | 2013 | 1492 | 0.060 |
Why?
|
Vascular Neoplasms | 1 | 2007 | 167 | 0.060 |
Why?
|
Sulfonamides | 2 | 2019 | 1982 | 0.060 |
Why?
|
Protein Processing, Post-Translational | 1 | 2013 | 1965 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 5 | 2001 | 1405 | 0.060 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 3427 | 0.060 |
Why?
|
Mice | 8 | 2015 | 81912 | 0.060 |
Why?
|
Vena Cava, Inferior | 1 | 2007 | 463 | 0.060 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 3928 | 0.060 |
Why?
|
Cycloheximide | 2 | 1994 | 340 | 0.060 |
Why?
|
Mutation, Missense | 1 | 2013 | 2592 | 0.060 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2744 | 0.050 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2010 | 2509 | 0.050 |
Why?
|
Body Weight | 1 | 2014 | 4627 | 0.050 |
Why?
|
Multiprotein Complexes | 1 | 2010 | 1110 | 0.050 |
Why?
|
Double-Blind Method | 3 | 2024 | 12451 | 0.050 |
Why?
|
Cells, Cultured | 4 | 2014 | 18989 | 0.050 |
Why?
|
Proteins | 3 | 2010 | 6001 | 0.050 |
Why?
|
Cell Movement | 1 | 2014 | 5203 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2019 | 6513 | 0.050 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2024 | 296 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2019 | 5186 | 0.050 |
Why?
|
Adolescent | 8 | 2024 | 89046 | 0.050 |
Why?
|
Nucleic Acid Hybridization | 2 | 1993 | 1305 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39317 | 0.050 |
Why?
|
DNA Mutational Analysis | 3 | 2016 | 4114 | 0.050 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2013 | 2186 | 0.050 |
Why?
|
Genes, p53 | 2 | 2011 | 711 | 0.040 |
Why?
|
Stomach Neoplasms | 1 | 2011 | 1481 | 0.040 |
Why?
|
Time Factors | 4 | 2024 | 40154 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 3530 | 0.040 |
Why?
|
Tumor Suppressor Proteins | 1 | 2010 | 2800 | 0.040 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 2 | 2012 | 367 | 0.040 |
Why?
|
Leukopenia | 1 | 2019 | 212 | 0.040 |
Why?
|
Genetic Testing | 1 | 2012 | 3591 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2019 | 6966 | 0.040 |
Why?
|
Cell Proliferation | 1 | 2014 | 10455 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2024 | 8535 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2001 | 376 | 0.040 |
Why?
|
DNA-Binding Proteins | 2 | 1993 | 9612 | 0.040 |
Why?
|
Transfection | 3 | 1996 | 5753 | 0.040 |
Why?
|
Cell Division | 2 | 1996 | 4473 | 0.040 |
Why?
|
Indazoles | 1 | 2019 | 306 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2019 | 9108 | 0.040 |
Why?
|
Anthracyclines | 1 | 2019 | 286 | 0.040 |
Why?
|
Tumor Burden | 2 | 2015 | 1903 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2015 | 16036 | 0.030 |
Why?
|
Carcinoma, Renal Cell | 1 | 2012 | 3186 | 0.030 |
Why?
|
Anorexia | 1 | 2017 | 153 | 0.030 |
Why?
|
Lipopolysaccharides | 1 | 2024 | 2217 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2013 | 7868 | 0.030 |
Why?
|
Cell Line, Transformed | 2 | 1996 | 861 | 0.030 |
Why?
|
Fibroblasts | 3 | 2000 | 4167 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15424 | 0.030 |
Why?
|
Signal Transduction | 3 | 2016 | 23621 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2012 | 4282 | 0.030 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 2 | 1993 | 153 | 0.030 |
Why?
|
Isoleucine | 1 | 1994 | 111 | 0.030 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 1997 | 434 | 0.030 |
Why?
|
Paresthesia | 1 | 2015 | 160 | 0.030 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2019 | 388 | 0.030 |
Why?
|
Neutropenia | 1 | 2019 | 892 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2015 | 254 | 0.030 |
Why?
|
Oligodeoxyribonucleotides | 2 | 1993 | 705 | 0.030 |
Why?
|
Nausea | 1 | 2017 | 682 | 0.030 |
Why?
|
RNA Probes | 1 | 1993 | 110 | 0.030 |
Why?
|
RNA, Messenger | 3 | 1993 | 12793 | 0.030 |
Why?
|
Cell Dedifferentiation | 1 | 2014 | 125 | 0.030 |
Why?
|
Taxoids | 1 | 2017 | 665 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2018 | 1604 | 0.030 |
Why?
|
Vomiting | 1 | 2017 | 655 | 0.030 |
Why?
|
G1 Phase | 1 | 1994 | 403 | 0.030 |
Why?
|
Gene Expression Regulation | 3 | 2000 | 11923 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2015 | 20741 | 0.030 |
Why?
|
Rats | 5 | 2000 | 23713 | 0.030 |
Why?
|
Child | 3 | 2024 | 80771 | 0.030 |
Why?
|
Retreatment | 1 | 2014 | 598 | 0.030 |
Why?
|
Embryo, Mammalian | 2 | 1996 | 1676 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2017 | 2227 | 0.020 |
Why?
|
3T3 Cells | 1 | 1993 | 1081 | 0.020 |
Why?
|
Perception | 1 | 2018 | 1205 | 0.020 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2014 | 631 | 0.020 |
Why?
|
Gene Rearrangement | 1 | 2017 | 1141 | 0.020 |
Why?
|
Collagen Type I | 1 | 2015 | 617 | 0.020 |
Why?
|
Purines | 1 | 2015 | 614 | 0.020 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 1992 | 286 | 0.020 |
Why?
|
Enhancer Elements, Genetic | 1 | 2018 | 1366 | 0.020 |
Why?
|
Cyclin-Dependent Kinases | 1 | 1994 | 661 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 1997 | 0.020 |
Why?
|
Tendons | 1 | 2015 | 556 | 0.020 |
Why?
|
Culture Media | 1 | 1993 | 892 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3944 | 0.020 |
Why?
|
Crystallography, X-Ray | 1 | 2015 | 1947 | 0.020 |
Why?
|
Retroviridae | 1 | 1993 | 846 | 0.020 |
Why?
|
Genes | 1 | 1993 | 1824 | 0.020 |
Why?
|
Molecular Weight | 1 | 1992 | 2168 | 0.020 |
Why?
|
Fatigue | 1 | 2017 | 1556 | 0.020 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 1992 | 326 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2017 | 1172 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2018 | 4280 | 0.020 |
Why?
|
Isoenzymes | 1 | 2013 | 1688 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 3611 | 0.020 |
Why?
|
Antigens, CD | 1 | 2019 | 4032 | 0.020 |
Why?
|
Cohort Studies | 3 | 2019 | 41718 | 0.020 |
Why?
|
Treatment Failure | 1 | 2014 | 2658 | 0.020 |
Why?
|
Cell Line | 3 | 2000 | 15567 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2021 | 3934 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3804 | 0.020 |
Why?
|
Base Sequence | 3 | 1996 | 12414 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 1993 | 1751 | 0.020 |
Why?
|
Gene Deletion | 1 | 2015 | 2668 | 0.020 |
Why?
|
Drug Discovery | 1 | 2015 | 1068 | 0.020 |
Why?
|
Estrogens | 1 | 1993 | 1536 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 1992 | 4167 | 0.020 |
Why?
|
RNA Interference | 1 | 2015 | 2829 | 0.020 |
Why?
|
Protein Biosynthesis | 1 | 1993 | 2093 | 0.020 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2010 | 667 | 0.020 |
Why?
|
Molecular Sequence Data | 3 | 1996 | 17608 | 0.020 |
Why?
|
Gastrectomy | 1 | 2011 | 693 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2018 | 8628 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2011 | 1741 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3266 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 1993 | 3738 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 1993 | 6226 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1992 | 6106 | 0.010 |
Why?
|
Survival Analysis | 1 | 2017 | 10092 | 0.010 |
Why?
|
Hippocampus | 1 | 1996 | 3777 | 0.010 |
Why?
|
Research Design | 1 | 2019 | 6210 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 1992 | 4616 | 0.010 |
Why?
|
Alleles | 1 | 1994 | 6893 | 0.010 |
Why?
|
Genetic Vectors | 1 | 1993 | 3402 | 0.010 |
Why?
|
DNA Damage | 1 | 1993 | 2469 | 0.010 |
Why?
|
Incidence | 1 | 2021 | 21526 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2011 | 2028 | 0.010 |
Why?
|
Repressor Proteins | 1 | 1993 | 2979 | 0.010 |
Why?
|
Child, Preschool | 1 | 2024 | 42606 | 0.010 |
Why?
|
United States | 1 | 2010 | 72971 | 0.010 |
Why?
|
Risk Factors | 2 | 2024 | 74886 | 0.010 |
Why?
|
Genes, bcl-2 | 1 | 2001 | 119 | 0.010 |
Why?
|
Contrast Media | 1 | 2014 | 5329 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18401 | 0.010 |
Why?
|
Zebrafish | 1 | 2011 | 3036 | 0.010 |
Why?
|
Antibodies, Neutralizing | 1 | 2010 | 2011 | 0.010 |
Why?
|
bcl-2-Associated X Protein | 1 | 2001 | 281 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2011 | 3468 | 0.010 |
Why?
|
Structure-Activity Relationship | 2 | 1996 | 3052 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2013 | 12536 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 1993 | 7611 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2010 | 2212 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2009 | 5311 | 0.010 |
Why?
|
Melanoma | 1 | 2017 | 5702 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5389 | 0.010 |
Why?
|
DNA | 1 | 1992 | 7210 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 2017 | 5859 | 0.010 |
Why?
|
Oncogene Protein pp60(v-src) | 1 | 1997 | 75 | 0.010 |
Why?
|
Neurons | 1 | 1996 | 9517 | 0.010 |
Why?
|
Amino Acid Chloromethyl Ketones | 1 | 1996 | 68 | 0.010 |
Why?
|
Culture Media, Serum-Free | 1 | 1996 | 147 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 1997 | 205 | 0.010 |
Why?
|
Genotype | 1 | 2011 | 13035 | 0.010 |
Why?
|
Antigens, Viral, Tumor | 1 | 1996 | 153 | 0.010 |
Why?
|
Simian virus 40 | 1 | 1996 | 291 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 1994 | 22361 | 0.010 |
Why?
|
Receptors, Growth Factor | 1 | 1997 | 324 | 0.010 |
Why?
|
Caspase 1 | 1 | 1996 | 227 | 0.010 |
Why?
|
bcl-X Protein | 1 | 1997 | 412 | 0.010 |
Why?
|
Androstadienes | 1 | 1997 | 348 | 0.010 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 1997 | 428 | 0.010 |
Why?
|
Cysteine Endopeptidases | 1 | 1996 | 542 | 0.010 |
Why?
|
Protease Inhibitors | 1 | 1996 | 750 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2009 | 6550 | 0.010 |
Why?
|
Sequence Deletion | 1 | 1996 | 1494 | 0.010 |
Why?
|
DNA Primers | 1 | 1996 | 2827 | 0.010 |
Why?
|
ras Proteins | 1 | 1997 | 1054 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 1993 | 1430 | 0.010 |
Why?
|
Carcinoma | 1 | 2001 | 2326 | 0.010 |
Why?
|
Kinetics | 1 | 1996 | 6287 | 0.000 |
Why?
|
Enzyme Inhibitors | 1 | 1997 | 3726 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1996 | 13411 | 0.000 |
Why?
|
Prostatic Neoplasms | 1 | 2001 | 11097 | 0.000 |
Why?
|